We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, diseasefree. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.
Orbital granulocytic sarcoma (GS) in pediatric patients is uncommon, and the treatment of GS is uncertain. [1] [2] [3] [4] Nonmyeloablative allogeneic stem cell transplantation has been reported by Slavin et al 5 to eradicate malignant host hematopoietic cells successfully. The aim of nonmyeloablative conditioning is to engraft donor immunohematopoietic cells to establish host-versus-graft tolerance for induction of graft-versus-malignant (GVM) effects to displace residual malignant host cells. The relatively low-intensity conditioning regimens decrease immediate procedural mortality and induce mixed chimerism to reduce the risk of graft-versushost disease (GVHD), thus improving immediate and longterm outcome. However, its use has not been reported in patients with GS. Here, we present a pediatric patient with AML, M2, with t(8;21)(q22;q22) and orbital GS with residual tumor after induction and three courses of consolidation chemotherapy, who received a nonmyeloablative allogeneic BMT with a successful result. 
Case report
A 3-year-old girl was referred to our ophthalmology department for evaluation of bilateral proptosis with a 2 month history. There was no significant past, or family medical history including maternal drug usage or radiation exposure during pregnancy. She had been in good health until 2 months prior to this visit when the parents found her to have eyelid swelling and proptosis on the right side, with gradual involvement of the left side.
Initial ocular examination disclosed a visual acuity of 20/20 in both eyes. The upper lids were edematous with palpable masses causing exophthalmos and proptosis. Corneal macula, keratitis, chemosis and trichisis were found, especially of the right eye. Her pupils were 5 mm bilaterally with normal reactivity to light and accommodation. Occular movement was normal in the left eye but the right eye did not fully adduct or abduct. Orbital MRI showed lobulated soft tissue masses with enhancement involving the orbits bilaterally, causing proptosis (Figure 1a ). Orbitotomy and tumor biopsy was performed and the pathologic diagnosis was granulocytic sarcoma. The hemogram checked at orbitotomy showed hemoglobin 12.4 g/dl, a white blood count of 11 700/l with 20% blasts and a platelet count of 287 000/l. Bone marrow aspirate and a chromosomal analysis disclosed AML, M2 with 45, −X, t(8;21)(q22;q22). No evidence of leukemic infiltration was documented on cytological examination of the cerebrospinal fluid. She was treated on the Taiwan Pediatric Oncology Group TPOG-AML-97A protocol. Three weeks after the initiation of chemotherapy with cytarabine 100 mg/m 2 once daily i.v. Residual soft tissue in the superior-lateral and right inferior aspect of the eyeballs bilaterally was shown on the orbital CT scan performed after the second course of chemotherapy and when she was in marrow remission.
Five months after the initiation of chemotherapy, allo- geneic BMT from a matched unrelated donor with nonmyeloablative conditioning was performed. The conditioning used originated from the regimen of Slavin et al, 5 ie six daily infusions of fludarabine (Fludara; Schering, Berlin, Germany) 30 mg/m 2 (days −10 to −5, total dose 180 mg/m 2 ); oral busulfan 4 mg/kg in divided doses daily for 2 consecutive days (days −6 to −5, total dose 8 mg/kg); and anti-T lymphocyte globulin (ATG; Fresenius, Munich, Germany) 10 mg/kg once daily i.v. for 4 consecutive days (days −4 to −1, total dose 40 mg/kg). The total number of nucleated cells infused on day 0 was 2.59 × 10 8 /kg. Cyclosporine A (CsA) 1.5 mg/kg twice daily i.v. starting from day −1 was used as GVHD prophylaxis, switching to an oral dose of 6.25 mg/kg twice daily as soon as the patient was able to tolerate an oral intake. Very few complications developed throughout the transplantation period. Only one short-term fever occurred due to a documented urinary tract infection that was controlled with antibiotics. The nadir of the absolute neutrophil count (ANC) was 0.2 × 10 9 /l on day +10, and this recovered to у0.5 × 10 9 /l on day +13, Ͼ1.0 × 10 9 /l on day +15. The nadir platelet count was 12 × 10 9 /l on day +16, rising to у20 × 10 9 /l on day +28, Ͼ100 × 10 9 /l on day +73; an overall Hb Ͼ8 gm/dl was achieved on day +87 (Figure 2 ). Throughout the whole procedure, the patient received 8 units of red blood cells and 6 units of pheresis platelets. Donor-recipient chimerism was monitored using automated fluorescence analysis of PCR (polymerase chain reaction)-amplified polymorphic STR (short tandem repeats) as previously described. 6 Mixed chimerism with 40% donor-type cells was detected 2 weeks after BMT and full donor chimerism occurred on day +28. CsA was tapered gradually and stopped on day +90. There was no acute GVHD, but limited chronic GVHD occurred 3 months after BMT. The subsequent orbital CT scans showed no residual tumor 4 months after BMT (Figure 1b) , and the patient is still experiencing leukemia-free survival 19 months after transplantation.
Discussion
Granulocytic sarcomas (GS), formerly known as chloromas, are extramedullary localized tumor masses comprising immature cells of the granulocytic series. They most commonly develop in bone and periosteum, especially in the skull, and proptosis attributable to orbital involvement has long been recognized as a classical clinical feature. 1 Our case illustrates a distinctive subset of granulocytic sarcoma that presents as proptosis preceding acute myeloid leukemia and which led to delayed diagnosis until the hematologic evidence of leukemia appeared 2 months later; the patient initially attended nephrology and ophthalmology clinics. When the orbital MRI revealed orbital masses, lymphoma was highly suspected. However, at tumor biopsy, the pre-operative hemogram unexpectedly revealed 20% blasts. From the experience of this patient and review of the literature, orbital masses as the initial presentation of AML should be considered in the differential diagnosis, even in the absence of typical leukemia symptoms.
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Zimmerman et al 1 suggested that any orbital tumor looking like a malignant lymphoma should be expected to be a granulocytic sarcoma and that appropriate hematologic studies should be undertaken.
GS have often been associated with t(8;21) in adults and children. Tallman et al 4 suggested that these patients might have a less favorable prognosis than AML patients with this translocation but no GS. The prognosis for untreated GS is poor. It has been shown that local treatments such as radiotherapy and intrathecal chemotherapy are ineffective even when there is no evidence of bone marrow disease. Vigorous chemotherapy should be administered as soon as a definitive histopathologic diagnosis is made, rather than waiting for the leukemic blood picture to emerge; aggressive therapy such as BMT may be warranted early.
Allogeneic BMT has been reported to be a part of successful treatment of GS by several authors. 4, 7, 8 Tallman et al 4 reported one case with persistent orbital GS and multiple GS in the right lung who was successfully treated with allo-BMT. Kowal-Vern et al 8 presented a case with GS of the ileum that was also successfully treated with surgical excision of the primary tumor and allo-BMT. It has been shown that allo-BMT is not only effective against malignancies by virtue of the conditioning but also because of a graft-versus-leukemia (GVL) effect. The efficacy of the GVL or graft-versus-tumor effect, as a positive counterpart of donor alloreactivity, has long been recognized on the experimental and clinical level. [9] [10] [11] An important point is whether or not the GVL effect exists in extramedullary lesions. Recently, Takada reported three cases of AML with existing or pre-existing intracerebral GS who were successfully treated with allo-BMT. One of their patients developed an optic nerve GS after suffering a bone marrow relapse. However, since their patients all received pre-transplant irradiation and chemotherapy followed by myeloablative conditioning, it is difficult to discern the role of GVL in this response. Conclusive evidence for the existence of a GVL effect in the CNS is still in doubt. Lee et al 12 observed a high frequency of extramedullary relapse of acute leukemia after allo-BMT, suggesting that GVL may be less effective in the extramedullary microenvironment. However, their patient group is small (50 patients only) and heterogeneous. The risk factors, such as development of GVHD, chromosomal abnormalities and cell surface markers contributing to extramedullary relapse had not been fully discussed. Also, the frequency (14%) of extramedullary relapse after allo-BMT in their report is much higher than in the analysis of Bekassy et al 13 from a large European multicenter survey (0.65% for AML group; 0.22% for CML/MDS group), thus making the role of a GVL effect on extramedullary disease ambiguous.
Slavin et al 14 reported that both extensive hematologic and extramedullary relapse can be reversed successfully by donor lymphocyte infusions (DLI). Another case report involved an isolated intrapulmonary GS following allo-BMT for AML, which was successfully treated with donor DLI. 15 These reports demonstrate that allogeneic donor lymphocytes which react with residual tumor cells of host origin, do exist in various extramedullary sites.
Chronic GVHD, which developed in this patient, has been reported to be associated with a decreased risk of recurrent leukemia and to contribute to improved survival Bone Marrow Transplantation after allo-BMT. 9, 10 An antileukemia effect directed against minor histocompatibility antigens could be exerted by allogeneic grafts, as part of an overt or subclinical graft-versushost reaction. Our patient had limited chronic GVHD after nonmyeloablative allo-BMT. Whether this regression of GS is related to chronic GVHD cannot be totally excluded.
Our patient was treated with the same aggressive chemotherapy as our AML patients and obtained partial response in her orbital mass. The residual orbital GS had been suggested as suitable for treatment with local irradiation; however, the parents of the patient worried about the long-term sequela of radiotherapy and refused. In an attempt to minimize the immediate and long-term therapy-related morbidity and mortality in this 3-year-old girl, and for the GVL effect to eradicate the residual GS, nonmyeloablative allo-BMT was suggested and the patient's parents consulted. After BMT, very little toxicity developed. Full donor chimerism was detected on day +28. The residual orbital lesions completely resolved 4 months post BMT. This patient is alive and still disease-free more than 19 months post BMT.
Our observations suggest that pediatric AML patients with t(8;21)(q22;q22) and residual orbital GS after intensive chemotherapy could benefit from nonmyeloablative allo-BMT. To our knowledge, this is the first case report utilizing nonmyeloablative allo-BMT to effectively treat a chemoresistant GS of the orbit. Because of the short observation period and only single-case experience, long-term follow-up of the anti-tumor efficacy of nonmyeloablative allogeneic stem cell transplantation and more studies comparing this approach with conventional therapy for AML patients with GS are warranted, especially for those with adverse prognostic chromosomal abnormalities.
